Edition:
India

People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

6.66USD
13 Dec 2019
Change (% chg)

$0.17 (+2.54%)
Prev Close
$6.49
Open
$6.47
Day's High
$6.70
Day's Low
$6.44
Volume
124,665
Avg. Vol
138,093
52-wk High
$12.57
52-wk Low
$3.35

Shreedhar, Vijay 

Mr. Vijay Shreedhar is Chief Commercial Officer of the Company. He joins Adamas from Amgen Inc. where he served in a variety of sales and marketing roles of increasing responsibility in multiple therapeutic areas including Inflammation, Osteoporosis, Oncology and Hematology. Most recently, he was Executive Director and Integrated Commercial Lead for the Multiple Myeloma franchise with responsibility for national sales, brand marketing and regional marketing teams. Vijay brings extensive US product commercial experience, successfully leading the market entry of new entities, expanded indications for approved products, as well as new drug-delivery systems. He has led strategy, sales and commercial execution for multiple Amgen brands, including Neulasta ® , XGEVA ® , Vectibix ® and Kyprolis , with a demonstrated track record of generating robust sales growth in highly competitive markets. Vijay started his career as a scientist in the field of Immuno-Oncology, earning his PhD at the University of Texas, M.D. Anderson Cancer Center and gaining experience in both academic and pharmaceutical research settings. He also earned an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --